熱門資訊> 正文
管弦乐团BioMed报告财政年度业绩
2024-03-28 04:52
- Orchestra BioMed press release (NASDAQ:OBIO): Net loss for 2023 was $49.1 million, or ($1.48) per share, compared with a net loss of $33.6 million, or ($2.24) per share, for 2022.
- Revenue for 2023 was $2.8 million, compared with $3.5 million for 2022.
- Cash and cash equivalents and marketable securities totaled $87.6 million as of December 31, 2023. Expected runway extended into the second half of 2026 based on internally prepared forecast reflecting updated operating priorities and certain potential future proceeds.
More on Orchestra BioMed
- Jefferies starts Orchestra BioMed at buy, cites lead program opportunities
- Seeking Alpha’s Quant Rating on Orchestra BioMed
- Historical earnings data for Orchestra BioMed
- Financial information for Orchestra BioMed
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
